SAN DIEGO, Aug. 11, 2016 /PRNewswire/ -- Plex Pharmaceuticals (registered as CalAsia Pharmaceuticals, Inc.) is pleased to announce the appointment of Dr. Arthur L. Horwich, MD as a member of the Scientific Advisory Board. Dr. Horwich is The Sterling Professor of Genetics and Pediatrics in the Department of Genetics, Yale University School of Medicine and is a Howard Hughes Medical Institute Investigator. He is a recipient of numerous awards, including The Albert and Mary Lasker Award for Basic Medical Research, The Rosenstiel Award for Distinguished Work in Basic Medical Science, The Shaw Prize in Life Science and Medicine and the 2016 Albany Medical Center Prize in Medicine and Biomedical Research.
"We are delighted to have Dr. Horwich join Plex," said Dr. Allan E. Rubenstein, MD, Chairman. "His strong experience in basic biology and translational research in the field of molecular chaperones combined with clinical expertise will greatly accelerate Plex's goal toward advancing our early stage drug discovery programs into identification of preclinical and clinical candidates as treatments for neurodegenerative disorders."
About Plex Pharmaceuticals: Plex Pharmaceuticals is an early stage biotechnology company which is focusing its drug discovery expertise on diseases caused by protein misfolding: ALS, Parkinson's disease and cataracts. CalAsia Pharmaceuticals, the predecessor to Plex Pharmaceuticals, was founded in 2009 and raised almost $3,000,000 in non-dilutive funding from the NIH and the Michael J. Fox Foundation to support its efforts in fragment-based screening and structure-based drug design. Plex's ALS effort is built around the work of Scientific Advisory Board member Dr. Arthur Horwich, Yale University School of Medicine. Dr. Horwich was one of the co-discoverers of the protein chaperone machinery, for which he received a Lasker Award. Plex Pharmaceuticals additionally has a development program for Dengue, West Nile and Zika antiviral drugs which has also received support from the NIH and has worked on a novel brain-penetrant heat shock protein 90 (HSP90) inhibitor for glioblastoma.
SOURCE Plex Pharmaceuticals